# Caris Life Sciences (CAI) — Analyst Forecast

CAI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cai/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 4 | 0 | 14 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $26.00 | $31.60 | $36.00 | 5 |

Last price $31.76 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 14, 2026 | JP Morgan | Maintained | Overweight | $35.00 |
| Oct 13, 2026 | TD Cowen | Maintained | Buy | $36.00 |
| Sep 9, 2026 | UBS | Initiated Coverage | Neutral | $28.00 |
| Aug 6, 2026 | Evercore ISI Group | Maintained | Outperform | $26.00 |
| Aug 6, 2026 | BTIG | Maintained | Buy | $33.00 |
| Jul 6, 2026 | Evercore ISI Group | Maintained | Outperform | $25.00 |
| Jul 2, 2026 | BTIG | Maintained | Buy | $32.00 |
| Jun 2, 2026 | Wolfe Research | Initiated Coverage | Peer Perform | — |
| May 8, 2026 | BTIG | Maintained | Buy | $32.00 |
| May 8, 2026 | JP Morgan | Maintained | Overweight | $30.00 |
| May 8, 2026 | Citigroup | Maintained | Buy | $28.00 |
| Apr 13, 2026 | Jefferies | Initiated Coverage | Buy | $28.00 |
| Apr 10, 2026 | Piper Sandler | Initiated Coverage | Neutral | $21.00 |
| Apr 6, 2026 | Evercore ISI Group | Maintained | Outperform | $30.00 |
| Mar 13, 2026 | Canaccord Genuity | Maintained | Hold | $22.00 |
| Feb 27, 2026 | BTIG | Maintained | Buy | $38.00 |
| Feb 27, 2026 | Evercore ISI Group | Maintained | Outperform | $34.00 |
| Feb 27, 2026 | Baird | Maintained | Outperform | $28.00 |
| Feb 17, 2026 | Baird | Initiated Coverage | Outperform | $26.00 |
| Dec 22, 2025 | Canaccord Genuity | Maintained | Hold | $30.00 |

## Frequently Asked Questions

### What is the price target for CAI stock?

The average 12-month analyst price target for Caris Life Sciences (CAI) is $31.60, with a high estimate of $36.00 and a low of $26.00, across 5 analysts.

### Is CAI a buy, sell, or hold?

Analysts covering Caris Life Sciences currently average a Buy rating: 10 buy, 4 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for CAI?

The average price target of $31.60 implies 0.50% downside from the last price of $31.76.

### What is the latest analyst rating on CAI?

On Oct 14, 2026, JP Morgan maintained Caris Life Sciences at Overweight with a price target of $35.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).